617 related articles for article (PubMed ID: 28625777)
1. Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients.
Gligorov J; Ataseven B; Verrill M; De Laurentiis M; Jung KH; Azim HA; Al-Sakaff N; Lauer S; Shing M; Pivot X;
Eur J Cancer; 2017 Sep; 82():237-246. PubMed ID: 28625777
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant Subcutaneous Trastuzumab for HER2-Positive Early Breast Cancer: Subgroup Analyses of Safety and Active Medical Conditions by Body Weight in the SafeHer Phase III Study.
Jung KH; Ataseven B; Verrill M; Pivot X; De Laurentiis M; Al-Sakaff N; Lauer S; Shing M; Gligorov J; Azim HA
Oncologist; 2018 Oct; 23(10):1137-1143. PubMed ID: 30018134
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: Final analysis of the randomised, two-cohort PrefHer study.
Pivot X; Verma S; Fallowfield L; Müller V; Lichinitser M; Jenkins V; Sánchez Muñoz A; Machackova Z; Osborne S; Gligorov J;
Eur J Cancer; 2017 Nov; 86():82-90. PubMed ID: 28963915
[TBL] [Abstract][Full Text] [Related]
4. Safety profile of subcutaneous trastuzumab for the treatment of patients with HER2-positive early or locally advanced breast cancer: primary analysis of the SCHEARLY study.
Zambetti M; Montemurro F; Morandi P; Zamagni C; Brandes AA; Bisagni G; Cagossi K; Bengala C; Gori S; Iannacone C; Stell A; Gianni L
Eur J Cancer; 2018 Dec; 105():61-70. PubMed ID: 30396014
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of adjuvant subcutaneous trastuzumab in human epidermal growth factor receptor 2-positive early breast cancer: Final results of the SafeHER study.
Gligorov J; Pivot X; Ataseven B; De Laurentiis M; Jung KH; Manikhas A; Abdel Azim H; Gupta K; Alexandrou A; Herraez-Baranda L; Tosti N; Restuccia E
Breast; 2022 Aug; 64():151-158. PubMed ID: 35487845
[TBL] [Abstract][Full Text] [Related]
6. Switching between intravenous and subcutaneous trastuzumab: Safety results from the PrefHer trial.
Gligorov J; Curigliano G; Müller V; Knoop A; Jenkins V; Verma S; Osborne S; Lauer S; Machackova Z; Fallowfield L; Pivot X
Breast; 2017 Aug; 34():89-95. PubMed ID: 28549309
[TBL] [Abstract][Full Text] [Related]
7. Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer.
Krop IE; Suter TM; Dang CT; Dirix L; Romieu G; Zamagni C; Citron ML; Campone M; Xu N; Smitt M; Gianni L
J Clin Oncol; 2015 Apr; 33(10):1136-42. PubMed ID: 25713436
[TBL] [Abstract][Full Text] [Related]
8. Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study.
O'Shaughnessy J; Sousa S; Cruz J; Fallowfield L; Auvinen P; Pulido C; Cvetanovic A; Wilks S; Ribeiro L; Burotto M; Klingbiel D; Messeri D; Alexandrou A; Trask P; Fredriksson J; Machackova Z; Stamatovic L;
Eur J Cancer; 2021 Jul; 152():223-232. PubMed ID: 34147014
[TBL] [Abstract][Full Text] [Related]
9. Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH study.
Jackisch C; Kim SB; Semiglazov V; Melichar B; Pivot X; Hillenbach C; Stroyakovskiy D; Lum BL; Elliott R; Weber HA; Ismael G
Ann Oncol; 2015 Feb; 26(2):320-5. PubMed ID: 25403587
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant Chemotherapy and Trastuzumab Is Safe and Effective in Older Women With Small, Node-Negative, HER2-Positive Early-Stage Breast Cancer.
Cadoo KA; Morris PG; Cowell EP; Patil S; Hudis CA; McArthur HL
Clin Breast Cancer; 2016 Dec; 16(6):487-493. PubMed ID: 27622751
[TBL] [Abstract][Full Text] [Related]
11. Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study.
Pivot X; Gligorov J; Müller V; Barrett-Lee P; Verma S; Knoop A; Curigliano G; Semiglazov V; López-Vivanco G; Jenkins V; Scotto N; Osborne S; Fallowfield L;
Lancet Oncol; 2013 Sep; 14(10):962-70. PubMed ID: 23965225
[TBL] [Abstract][Full Text] [Related]
12. Development of a Subcutaneous Fixed-Dose Combination of Pertuzumab and Trastuzumab: Results From the Phase Ib Dose-Finding Study.
Kirschbrown WP; Wynne C; Kågedal M; Wada R; Li H; Wang B; Nijem I; Badovinac Crnjevic T; Gasser H; Heeson S; Eng-Wong J; Garg A
J Clin Pharmacol; 2019 May; 59(5):702-716. PubMed ID: 30570763
[TBL] [Abstract][Full Text] [Related]
13. HannaH phase III randomised study: Association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant-adjuvant trastuzumab after 2 years of treatment-free follow-up.
Jackisch C; Hegg R; Stroyakovskiy D; Ahn JS; Melichar B; Chen SC; Kim SB; Lichinitser M; Starosławska E; Kunz G; Falcon S; Chen ST; Crepelle-Fléchais A; Heinzmann D; Shing M; Pivot X
Eur J Cancer; 2016 Jul; 62():62-75. PubMed ID: 27208905
[TBL] [Abstract][Full Text] [Related]
14. Safety profile of subcutaneous trastuzumab in patients with HER2-positive early breast cancer: The French HERmione non-interventional prospective study.
Jacquin JP; Uwer L; Savignoni A; Ferrero JM; Lortholary A; Solub D; Delaporte F; Chalabi N; Pibre S; Belkacemi Y
Breast; 2020 Feb; 49():1-7. PubMed ID: 31670262
[TBL] [Abstract][Full Text] [Related]
15. Superimposable outcomes for sequential and concomitant administration of adjuvant trastuzumab in HER2-positive breast cancer: Results from the SIGNAL/PHARE prospective cohort.
Pivot X; Fumoleau P; Pierga JY; Delaloge S; Bonnefoi H; Bachelot T; Jouannaud C; Bourgeois H; Rios M; Soulié P; Jacquin JP; Lavau-Denes S; Kerbrat P; Cox D; Faure-Mercier C; Pauporte I; Gligorov J; Curtit E; Henriques J; Paget-Bailly S; Romieu G
Eur J Cancer; 2017 Aug; 81():151-160. PubMed ID: 28624696
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetic and exposure-response analysis for trastuzumab administered using a subcutaneous "manual syringe" injection or intravenously in women with HER2-positive early breast cancer.
Quartino AL; Hillenbach C; Li J; Li H; Wada RD; Visich J; Li C; Heinzmann D; Jin JY; Lum BL
Cancer Chemother Pharmacol; 2016 Jan; 77(1):77-88. PubMed ID: 26645407
[TBL] [Abstract][Full Text] [Related]
17. Neo-adjuvant and/or Adjuvant Subcutaneous Trastuzumab (Herceptin
Schmidt M; KÜmmel S; Ruf-Doerdelmann A; Distelrath A; Wacker J; Schmatloch S; Busch-Liles S; LÜdtke-Heckenkamp K
Anticancer Res; 2021 Jan; 41(1):485-496. PubMed ID: 33419847
[TBL] [Abstract][Full Text] [Related]
18. Trastuzumab for patients with HER2 positive breast cancer: delivery, duration and combination therapies.
Pinto AC; Ades F; de Azambuja E; Piccart-Gebhart M
Breast; 2013 Aug; 22 Suppl 2():S152-5. PubMed ID: 24074778
[TBL] [Abstract][Full Text] [Related]
19. Trastuzumab retreatment after relapse on adjuvant trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer: final results of the Retreatment after HErceptin Adjuvant trial.
Láng I; Bell R; Feng FY; Lopez RI; Jassem J; Semiglazov V; Al-Sakaff N; Heinzmann D; Chang J
Clin Oncol (R Coll Radiol); 2014 Feb; 26(2):81-9. PubMed ID: 24051172
[TBL] [Abstract][Full Text] [Related]
20. Subcutaneous Trastuzumab: A Review in HER2-Positive Breast Cancer.
Heo YA; Syed YY
Target Oncol; 2019 Dec; 14(6):749-758. PubMed ID: 31686307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]